Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) EPS (Basic): 2015-2025

Historic EPS (Basic) for Spyre Therapeutics (SYRE) over the last 11 years, with Sep 2025 value amounting to -$5.97.

  • Spyre Therapeutics' EPS (Basic) rose 85.87% to -$5.97 in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.07, marking a year-over-year increase of 87.71%. This contributed to the annual value of -$127.21 for FY2024, which is 76.88% up from last year.
  • Latest data reveals that Spyre Therapeutics reported EPS (Basic) of -$5.97 as of Q3 2025, which was up 69.57% from -$19.62 recorded in Q2 2025.
  • Spyre Therapeutics' 5-year EPS (Basic) high stood at $40.14 for Q2 2023, and its period low was -$564.94 during Q4 2023.
  • Over the past 3 years, Spyre Therapeutics' median EPS (Basic) value was -$23.61 (recorded in 2024), while the average stood at -$64.06.
  • Within the past 5 years, the most significant YoY rise in Spyre Therapeutics' EPS (Basic) was 14,966.67% (2023), while the steepest drop was 11,945.63% (2023).
  • Spyre Therapeutics' EPS (Basic) (Quarterly) stood at -$24.33 in 2021, then surged by 80.72% to -$4.69 in 2022, then crashed by 11,945.63% to -$564.94 in 2023, then soared by 94.42% to -$31.53 in 2024, then skyrocketed by 85.87% to -$5.97 in 2025.
  • Its EPS (Basic) stands at -$5.97 for Q3 2025, versus -$19.62 for Q2 2025 and -$23.95 for Q1 2025.